Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Can

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06841159 by Fudan University, with a registry enrolment figure of 116 participants, started 2024-03-01 and due to reach its primary completion in 2026-03-01. Interventions recorded: Ultra-fractionated radiation therapy; Sintilimab; Standard systemic therapy. Conditions listed: Microsatellite Stable Metastatic Colorectal Cancer. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "* Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.